Back to search

Article

Immunogenicity and Reactogenicity of a First Booster with NT162b2or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1)

2023-06-02

Abstract excerpt

Background: Vaccination remains crucial for protection against severe SARS-CoV-2 infection, especially for people of advanced age, however, optimal dosing regimens are as yet lacking.<br><br>Methods: EU-COVAT-1-AGED Part A is a randomised controlled, adaptive, multicentre phase II trial evaluating safety and immunogenicity of a 3<sup>rd</sup> vaccination (1<sup>st</sup> booster) in individuals ≥75 years. Fifty-thr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c9b67d8e-5e90-5177-9dee-7fdbd62e8ed8
DOI
10.2139/ssrn.4464860
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immunogenicity and Reactogenicity of a First Booster with NT162b2or Full-Dose mRNA-1273: A Randomised VACCELERATE Trial in Adults ≥75 Years (EU-COVAT-1)DOI 10.2139/ssrn.4464860
STUDY PROTOCOL A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): A trial conducted within the VACCELERATE networkSemantic proximity
Immunogenicity and Reactogenicity of Heterologous and Homologous mRNA-1273 and BNT162b2 Vaccination: A Multicenter Non-Inferiority Randomized TrialSemantic proximity
Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.SSemantic proximity
Immunogenicity and Safety of COVID-19 Booster Vaccination: A Real-World Clinical Trial to Identify the Best Vaccination StratagySemantic proximity
Age-related heterogeneity in immune responses to SARS-CoV-2 following BNT162b2 vaccinationSemantic proximity
Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity
Humoral and Cellular Immunity to SARS-CoV-2 Vaccination in Cancer Patients: Completed Prospective Observational Study Using BNT162b2 mRNA VaccineSemantic proximity
Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-upSemantic proximity
Immune Response and Reactogenicity After Immunization With a Suboptimal Two-Dose mRNA Vaccine Followed by a Full Vaccination With a Standard mRNA Vaccine Compared to a Prime-Boost Regimen of a Standard mRNA Vaccine: A Multicenter Cohort StudySemantic proximity
Serum Neutralizing Activity of mRNA-1273 Against the SARS-CoV-2 B.1.1.529 (Omicron) Variant: A Preliminary ReportSemantic proximity
Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)Semantic proximity
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim AnalysisSemantic proximity
Select a neighboring publication to make it the new centre.